Alzinova initiates development of a stable cell line to prepare the monoclonal antibody ALZ-201 for Alzheimer’s clinical trials
Alzinova AB (publ) (“Alzinova” or the “Company”) today announces the initiation of the next step in the preclinical development of its oligomer-specific monoclonal antibody, ALZ-201. The Company is developing ALZ-201 as a second product in its portfolio of Alzheimer’s treatments, along with its vaccine candidate, ALZ-101, which is currently in Phase 1b clinical development.The Company has now initiated the development of a stable cell line to produce high and consistent levels of ALZ-201. In this process, the goal is to isolate single, viable, and high-producing cell clones to ensure